Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia.

Blood advances - 12 Dec 2023

Syrykh Charlotte, Pons-Brun Berta, Russiñol Núria, Playa-Albinyana Heribert, Baumann Tycho, Duran-Ferrer Martí, Kulis Marta, Carbó-Meix Anna, Mozas Pablo, Alcoceba Miguel, González Marcos, Navarro-Bailón Almudena, Colado Enrique, Payer Ángel R, Aymerich Marta, Terol María J, Lu Junyan, Knisbacher Binyamin A, Hahn Cynthia K, Ruiz-Gaspà Sílvia, Enjuanes Anna, Wu Catherine J, Getz Gad, Zenz Thorsten, López-Guillermo Armando, Martín-Subero José I, Colomer Dolors, Delgado Julio, Campo Elías, Nadeu Ferran

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunoglobulin Heavy Chains
Share to Leukemia, Lymphocytic, Chronic, B-Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 37505099
DOI: 10.1182/bloodadvances.2023010132
PMCID: PMC10726246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia.PMID 37505099Read ↗

IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.Semantic proximity Read ↗

IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.Semantic proximity Read ↗

The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study.Semantic proximity Read ↗

IGLV3-21 <sup>R110</sup> -directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemiaSemantic proximity Read ↗

Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.Semantic proximity Read ↗

Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study.Semantic proximity Read ↗

IgVH mutations in patients with chronic lymphocytic leukemia.Semantic proximity Read ↗

Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

Mutation-specific CAR T cells as precision therapy for IGLV3-21 <sup>R110</sup> expressing high-risk chronic lymphocytic leukemiaSemantic proximity Read ↗

Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia.Semantic proximity Read ↗

Use of IGHV3–21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post–germinal center leukemogenic selectionSemantic proximity Read ↗

Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.